An Open-label, Long-term Study to Evaluate the Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
Phase of Trial: Phase II/III
Latest Information Update: 13 Apr 2018
Price : $35 *
At a glance
- Drugs Bimagrumab (Primary)
- Indications Inclusion body myositis
- Focus Adverse reactions; Registrational
- Sponsors Novartis
- 06 Oct 2016 Status changed from active, no longer recruiting to completed.
- 08 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 03 Mar 2015 Planned End Date changed from 1 May 2017 to 1 Jan 2018 according to ClinicalTrials.gov record.